AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Recommendation of “Buy” by Analysts
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $3.42.
Several research analysts have recently issued reports on AVEO shares. Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Monday, July 24th. Piper Jaffray Companies upped their price objective on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the company an “overweight” rating in a research note on Monday, August 28th. FBR & Co reaffirmed an “outperform” rating and issued a $3.00 price objective on shares of AVEO Pharmaceuticals in a research note on Thursday, July 13th. BidaskClub raised AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 16th. Finally, ValuEngine raised AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 24th.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 3.95 on Friday. The stock’s 50 day moving average is $3.58 and its 200 day moving average is $1.91. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $4.24. The firm’s market cap is $467.31 million.
Institutional investors have recently added to or reduced their stakes in the company. Fore Research & Management LP acquired a new position in shares of AVEO Pharmaceuticals in the second quarter valued at approximately $111,000. Clear Harbor Asset Management LLC acquired a new position in shares of AVEO Pharmaceuticals in the second quarter valued at approximately $289,000. Cannell Peter B & Co. Inc. increased its stake in shares of AVEO Pharmaceuticals by 22.9% in the second quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 20,500 shares during the period. Paloma Partners Management Co acquired a new position in shares of AVEO Pharmaceuticals in the first quarter valued at approximately $184,000. Finally, UBS Oconnor LLC acquired a new position in shares of AVEO Pharmaceuticals in the first quarter valued at approximately $291,000. 53.76% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/06/aveo-pharmaceuticals-inc-aveo-given-consensus-recommendation-of-buy-by-analysts.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.